In-Situ gel: New trends in controlled and sustained drug delivery system

International Journal of PharmTech Research

Volumn 2, Issue 2, 2010, Pages 1398-1408

  Nirmal, H B ^a   Bakliwal, S R ^a   Pawar, S P ^a  

^a PSGVPM's College of Pharmacy   (India)

Author keywords

Biodegradable polymers; Controlled release; In situ gels; Poly (lactic co glycolic acid); Sustained release

Indexed keywords

ALGINIC ACID; CHITOSAN; GELLAN; PECTIN; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; POLYMER;

ARTICLE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MANUFACTURE; GEL; PATIENT COMPLIANCE; PATIENT SATISFACTION; PH; SUSTAINED DRUG RELEASE; TEMPERATURE; ULTRAVIOLET IRRADIATION;

EID: 77954735684     PISSN: None     EISSN: 09744304     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Peppas N, Langer R. New challenges in biomaterials. Science 1994; 263:171520.
2. Zhidong L,Jaiwei L, Shufang N, Hui L, Pingtian D, Weisan P. Study of an Pharm alginate-HPMC based in situ gelling ophthalmic delivery system for gatifloxacin. Int J. 2006; 315:127.
3. Sarasija S, Shyamala B. Nasal Drug Delivery: An Overview, Indian J Pharm.Sci. 2005, 67(1): 1925.
4. Wataru K, Yasuhiro K, Miyazaki S, Attwood D. In situ gelling pectin formulations for oral sustained delivery of paracetamol. Drug Develop Ind Pharm 2004;30:593-9.
5. Marsha Ritter Jones, MS, Philip B. Massersmith, In-situ forming biomaterials, Oral Maxillofacial Surg Clin N Am 14 (2002):29-38
6. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm 2000;
7. Qiu Y, Park K. Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 2001;53:321-39.
8. Bromberg LE, Ron ES. Temperature-responsive gels and thermogelling polymer matrices for protein and peptide delivery. Adv Drug Deliv Rev 1998;31:197-221.
9. Cappello J, Crissman JW, Crissman M, Ferrari FA, Textor G, Wallis O, et al. In-situ self-assembling protein polymer gel systems for administration, delivery, and release of drugs. J Control Release 1998;53:105-17.
10. Soppimath KS, Aminabhavi TM, Dave AM, Kumbar SG, Rudzinski WE. Stimulus-responsive smart hydrogels as novel drug delivery systems. Drug Dev Ind Pharm 2002;28: 957-74.
11. Aikawa K, Mitsutake A, Uda H, Tanaka S, Shimamura H, Aramaki Y, et al. Drug release from pH-response polyvinylacetal diethyl aminoacetate hydrogel, and application to nasal delivery. Int J Pharm 1998;168:181-8.
12. Kumar S, Himmelstein K. Modification of in-situ gel behaviour of Carbopol solutions by hydroxypropylmethylcellulose.J.Pharm.Sci.1995;8 4:344-8.
13. Alexandridis P, Lindman B, Amphiphilicblock polymers. Amsterdam:Elsvier;2000
14. Esposito E, Carratto V & et al.Comparative analysis of tetracycline containing dental gels; poloxomers and mono-glycerides based formulation. Int.J.Pharm.1996;142:9-23.
15. Geraghaty P, Attwood D, et al. An investigation of parameters influencing the Bioadhesive properties of Myverol 18-99/ water gels. Biomaterials 1997, 18:63-7.
16. Motto F, Gailloud P, et al., In-vitro assessment of new embolic liquids prepared from preformed polymers and water miscible solvents aneurysm treatment. Biomaterials 2000,21:803-11
17. Bhardwaj TR, Kanwar M, Lal R, Gupta A. Natural gums and modified natural gums as sustained-release carriers. Drug Devel Ind Pharm 2000;26:1025-38.
18. Guo J-H, Skinner GW, Harcum WW, Barnum PE. Pharmaceutical applications of naturally occurring water-soluble polymers. Pharm Sci & Technol Today 1998;1:254-61.
19. Podual K, Doyle III FJ, Peppas NA. Dynamic behavior of glucose oxidase-containing microparticles of poly(ethylene)-grafted cationic hydrogels in an environment of changing pH. Biomaterials 2000;21:1439-50.
20. Burkoth AK, Anseth KS. A review of photocrosslinked polyanhydrides: In situ forming degradable networks. Biomaterials 2000;21:2395-404.
21. Sawhney AS, Pathak CP, Hubbell JA, Hill JL, Desai NP. Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled release carriers. US Patent 5410016. 1995.
22. Dumitriu S, Vidal PF, Chornet E. Hydrogels based on polysaccharides. In: Dumitriu.S, editor. Polysaccharides in medical applications. New York: Marcel Dekker Inc; 1996. p. 125-242.
23. Ni Y, Kenneth MY. In-situ gel formation of pectin. 2004. United States Patent 6777000.
24. Miyazaki S, Kawasaki N. Comparison of in situ gelling formulations for the oral delivery of cimetidine. Int J Pharm 2001;220:161-8.
25. Bilensoy E, Rouf MA, Imran V, Murat S, Hincal AA. Mucoadhesive thermosensitive prolonged release vaginal gel for clotrimazole: β-cyclodextrin complex. AAPS Pharm Sci Tech 2006;7:38.
26. Miyazaki S, Suisha F, Kawasaki N. Thermally reversible xyloglucan gels as vehicles for rectal drug delivery. J Control Rel 1998;56:75-83.
27. Kawasaki N, Ohkura R, Miyazaki S, Uno Y, Sugimoto S, Attwood D. Thermally reversible xyloglucan gels as vehicles for oral drug delivery. Int J Pharm 1999;181:227-34.
28. Suisha F, Kawasaki N, Miyazaki S, Shirakawa M, Yamotoya K, Sasaki M, et al. Xyloglucan gels as sustained release vehicles for intraperitoneal administration of mitomycin C. Int J Pharm 1998;172:27-32.
29. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001;229:29-36.
30. Miyazaki S, Hirotatsu A, Kawasaki N, Wataru K, Attwood D. In situ gelling gellan formulations as vehicles for oral drug delivery. J Control Rel 1999;60:287-95.
31. Crescenzi V, Dentini M, Coviello T. Solutions and gelling properties of microbial polysaccharides of industrial interest: The case of gellan. In: Dawes EA, editor. Novel biodegradable microbial polymers. Dordrecht: Kluwer Academic Publishers; 199: 227-84.
32. Grasdalen H, Smidsroed O. Gelation of gellan gum. Carbohydrate Polymers 1987;7:371-93.
33. Sechoy O, Tissie G, Sebastian C, Maurin F, Driot JY, Trinquand C. A new long acting ophthalmic formulation of carteolol containing Alginic acid. Int J Pharm 2000;207:109-16.
34. Smart JD, Kellaway IW, Worthington HE. An in vivo investigation of mucosa adhesive materials for use in controlled drug delivery. J Pharm Pharmacol 1984;36:259-99.
35. Al-Shamklani A, Bhakoo M, Tuboku MA, Duncan R. Evaluation of the biological properties of alginates and gellan and xanthan gum. Proc Int Symp Control Release Bioact Mater 1991;18:213-4.
36. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. J Control Release 2002;80:9-28.
37. Chenite A, Chaput C, Wang D, Combes C, Buschmann MD, Hoemann CD et al. Novel injectable solution of chitosan form biodegradable gels in situ. Biomaterials 2000;21:2155-61.
38. Ismail FA, Napaporn J, Hughes JA, Brazean GA. In situ gel formulation for gene delivery: release and myotoxicity studies. Pharm Dev Technol 2000;5:391-7.
39. Schmolka IR: Artificial skin, Preparation and properties of pluronic F127 gels for the treatment of burns. J. Biomed. Mater. Res. 6:571-582, 1972.
40. Kabanov A, Batraoka E, Alakhov V: Pluronic block copolymers as novel polymer therapeutics for oral and gene delivery. J. Control. Rel. 82:189212, 2002.
41. Alexandridis P, Hatton TA. Poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide) block copolymer surfactants in aqueous solutions and interfaces: thermodynamics, structure, dynamics and modeling. Colloid Surfaces 1995; A96:146.
42. Liu F, Wilson BC. Hyperthermia and photodynamic therapy. In: Tannock I, Hill RP, editors. Basic science of oncology. New York: McGraw-Hill; 1998. p. 443-53.
43. Dunn RL, English JP, Cowsar DR, Vanderbelt DD. Biodegradable in situ forming implants and methods for producing the same. US Patent 5340849 1994.
44. Siegel RA, Firestone BA. pH dependent equilibrium swelling properties of hydrophobic poly electrolyte copolymer gels. Macromolecules 1988;21:3254-9.
45. Eliassaf J. Aqueous solution of poly-(N-isopropyl acrylamide). J App Polymer Sci 1978; 22:873-4.
46. Illum L., Fisher A.N, Jabbal-Gill I, Davis S.S, Bioadhesivestarch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides; Int. J. Pharm., 222 (2001),109-119.
47. Chein Y.W., Novel drug delivery systems, Marcel Dekker Inc.50 (2), 1982, 229-260.
48. Mikkelson TJ. Ophthalmic drug delivery. Pharm Tech 1984;8:90-8.
49. Miyazaki S, Suzuki S, Kawasaki N, Endo K, Takahashi A, Attwood D. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. Int J Pharm 2001;229:29-36.
50. Schoenwald RD. Ocular drug delivery: Pharmacokinetic considerations. Clin Pharma cokinet 1990;18:255-69.
51. Cao S, Ren X, Zhang Q, Chen E, Xu F, Chen J, et al. In situ gel based on gellan gum as new carrier for nasal administration of mometasone furoate. Int J Pharm 2009;365:109-15.
52. Wu J, Wei W, Wang LY, Su ZG, Ma G. A thermosensitive hydrogel based on quaternized chitosan and poly (ethylene glycol) for nasal delivery system. Biomaterials 2007;28:2220-32.
53. Ito T, Yeo Y, Highley CB, Bellas E, Benitez CA, Kohane DS. The prevention of peritoneal adhesions by in situ cross-linking hydrogels of hyaluronic acid and cellulose derivatives. Biomaterials 2007;28:975-83.
54. Kashyap N, Viswanad B, Sharma G, Bhardwaj V, Ramarao P, Kumar MNV. Design and evaluation of biodegradable, biosensitive in situ gelling systems for pulsatile delivery of insulin. Biomaterials 2007; 28:2051-60.
55. Kashyap N, Viswanad B, Sharma G, Bhardwaj V, Ramarao P, Kumar MNV. Design and evaluation of biodegradable, biosensitive in situ gelling systems for pulsatile delivery of insulin. Biomaterials 2007;28:2051-60.
56. Chandrashekhar G, Udupa N. Biodegradable injectable implant system for long term drug delivery using poly (lactic-co-glycolic) acid copolymers. J Pharm Pharmacol 1998; 48:669-74.
57. Sambhaji Pisal, 1 Vijay Shelke, et al., Effect of Organogel Components on In Vitro Nasal Delivery of Propranolol Hydrochloride, AAPS PharmSciTech 2004; 5:4,63
58. Plourde F, Motulsky A, Couffin-Hoarau AC, Hoarau D, Ong H, Leroux JC. First report on the efficacy of l-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs. J Control Release 2005;108:433-41.
59. ;, 0.25% and 0.5%, (Timolol maleate ophthalmic gel forming solution), Merck and Company Inc. NJ 08889: Whitehouse Station, USA.
60. Ramesh CR, Zentner GM, Jeong B. Macro med, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US patent 6201072. 2001.
61. Rathi R, Zentner C, Gaylen M, Jeong B. Macro med, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties. US patent 6117949. 2000.